Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685819 | 0.84 | TRPA1 (0.39) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL22281317 | 0.80 | TRPA1 (0.42) | IDO1CDK2FLT3CCNA1NOS1 | |
| SCHEMBL21216406 | 0.80 | IDO1 (0.51) | NR3C1IDO1NOS1AXLTRPV1 | |
| SCHEMBL23732643 | 0.72 | AKT2 (0.32) | — | |
| SCHEMBL24094124 | 0.71 | NOS1 (0.41) | ESR2ESR1IDO1CDK2NOS1 | |
| SCHEMBL21952718 | 0.71 | TRPA1 (0.40) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL20439436 | 0.70 | TRPA1 (0.42) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL21217948 | 0.70 | TRPA1 (0.39) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL8404436 | 0.69 | IDO1 (0.46) | ESR2ESR1IDO1CDK2FLT3 | |
| SCHEMBL18430266 | 0.68 | NOS1 (0.45) | CDK2NOS1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ESR2 2425/4885ESR1 4519/4885NR3C1 2864/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ESR2 2425/4885ESR1 4519/4885NR3C1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.